Human Albumin Csl Behring (Human Plasma Protein)

Human Albumin CSL Behring is used in clinical settings to restore and maintain circulating blood volume. It is indicated for conditions where plasma oncotic pressure is reduced or where rapid volume expansion is required.

• Treatment of hypovolemia due to trauma, surgery, or fluid loss
• Management of shock and severe burns
• Support for patients with hypoalbuminemia, such as in liver disease
• Volume replacement during cardiac surgery and cardiopulmonary bypass
• Adjunct therapy in patients with severe sepsis or systemic inflammatory response

• Human Albumin CSL Behring increases plasma oncotic pressure by adding exogenous albumin to the intravascular compartment. The elevated oncotic gradient draws water from the interstitial space into the vascular lumen, expanding circulating blood volume and improving tissue perfusion without directly affecting cardiac contractility or vascular tone.

Adverse reactions to Human Albumin CSL Behring can vary in frequency and severity.

Common

• Fever or chills
• Mild hypotension or hypertension
• Headache
• Nausea or vomiting
• Local irritation at the infusion site
• Transient rash or urticaria

Serious

• Anaphylactic or severe allergic reactions
• Acute hemolysis
• Pulmonary edema due to fluid overload
• Thromboembolic events
• Severe hypertension or cardiovascular collapse

Human Albumin CSL Behring should be administered with careful clinical assessment. Consider the following precautions:

• Evaluate fluid status and cardiac function before infusion
• Monitor vital signs and urine output during and after administration
• Use caution in patients with renal or hepatic impairment
• Avoid rapid infusion rates to reduce risk of circulatory overload
• Assess for known hypersensitivity to human albumin products
• Adjust dose in patients with severe burns or capillary leak syndrome
• Document any adverse reactions promptly

Human Albumin CSL Behring may interact with other therapies that affect fluid balance or coagulation.

Avoid

• Concurrent use of high‑dose diuretics without monitoring volume status
• Simultaneous administration of other plasma expanders that could cause overload

Use with caution

• Vasopressor agents, as changes in intravascular volume may alter hemodynamic response
• Anticoagulants, because volume expansion can affect bleeding risk
• Steroids or immunosuppressants, which may mask allergic reactions
• Blood products, to prevent additive volume overload
• Medications that influence renal function, requiring close monitoring